Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE3.0300
- TODAY'S CHANGE (%)0.0300 (1.0000%)
- Bid / Lots3.0100/ 5
- Ask / Lots3.0400/ 5
- Open / Previous Close3.0100 / 3.0000
- Day Range
- 52 Week Range
- Volume34,672
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KOD |
|---|---|---|
| 09:32 ET | 4218 | 2.99 |
| 09:34 ET | 300 | 2.97 |
| 09:38 ET | 950 | 2.9531 |
| 09:39 ET | 2633 | 2.9607 |
| 09:43 ET | 750 | 2.95 |
| 09:45 ET | 505 | 2.96 |
| 09:48 ET | 9661 | 3 |
| 09:50 ET | 934 | 3.03 |
| 09:56 ET | 2645 | 3.05 |
| 09:57 ET | 700 | 3.02 |
| 09:59 ET | 4185 | 3.03 |
| 10:01 ET | 3240 | 3.03 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 157.6M | -0.7x | --- |
Elevation Oncology Inc | 157.4M | -2.8x | --- |
Vicapsys Life Sciences Inc | 160.4M | -152.8x | --- |
Vigil Neuroscience Inc | 163.5M | -2.1x | --- |
Context Therapeutics Inc | 151.5M | -1.5x | --- |
Atossa Therapeutics Inc | 164.7M | -5.6x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Lead Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $157.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.39 |
EPS | $-4.44 |
Book Value | $5.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
